fbpx
01 / 05
The Misleading Arithmetic of COVID-19 Death Rates

Blog Post | Health & Medical Care

The Misleading Arithmetic of COVID-19 Death Rates

Minor, nonfatal cases of coronavirus often go unreported.

Assuming the number of people who have reportedly died from COVID-19 is reasonably accurate, then the percentage of infected people who die from the disease (the death rate) must surely have been much lower than the 2–3% estimates commonly reported. That is because the number of infected people is much larger than the number tested and reported.

The triangle graph, from a February 10 study from Imperial College London, shows that most people infected by COVID-19 are never counted as being infected. That is because, the Imperial College study explains, “the bottom of the pyramid represents the likely largest population of those infected with either mild, non‐​specific symptoms or who are asymptomatic.”

As the Director General of the World Health Organization (WHO), Tedros Adhanom, explained in his February 28 briefing, “Most people will have mild disease and get better without needing any special care.” Several studies have found that about 80% of all the COVID-19 cases have relatively minor symptoms which end without severe illness and therefore remain unreported.

A Chinese study in the Journal of the American Medical Association, February 20, found a “case‐​fatality rate” of 2.3%, meaning 1,023 died out of 44,672 cases. But the total sample in that study (72,314) included an additional 27,642 non‐​confirmed cases, and simply including those cases (let alone unreported minor cases) would have reduced the fatality rate to 1.4%.

China‐​based estimates are largely confined to cases with the most severe symptoms, so it should be no surprise that the reported death rate among severe cases is much higher than it would be if the data also included “most people” who “have a mild disease and get better.” The risk of infecting more people is also more severe in China data, since severe cases are concentrated and transmitted in hospitals. This can also lead to overstated estimates of how many people are infected by someone with COVID-19, including the WHO “reproduction number” estimate of 1.4–2.5, which is mainly based on evidence from China.

As the graph indicates, other countries include more non‐​severe cases than China does, notably by testing incoming travelers who arrive with a cough and fever. Even after casting a slightly wider net, however, the number of confirmed cases probably captures only about 30% of the actual number.

By the morning of March 2, there had been 89,253 confirmed cases of COVID-19 reported around the world, with about 96% of those in Asia. For comparison, there were an estimated 37.9 million people living with HIV in 2018.

It is worth noting that there have also been 45,393 known recoveries from COVID-19 (compared to 3048 cumulative deaths) and, importantly, recoveries have been outnumbering new cases.

What about the relatively small number of COVID-19 cases outside China? In his February 28, the Director General of WHO reported that “Outside China, there are now 4351 cases in 49 countries, and 67 deaths.” Deaths of 67 divided by 4351 seems to demonstrate a death rate of 1.5%. But such calculations are highly misleading. They assume the denominator of that ratio (4351) is as accurate as the numerator (67). Yet people with “mild cases who get better” are unlikely to ever be included in the denominator.

If the WHO estimate of 4351 confirmed cases amounted to 30% of the actual number infected outside of China at that time, for example, then the combined total of both unreported and confirmed cases would be 4351 divided by 0.30 or 14,503. In that case, the actual death rate would 67 divided by 14,503, or less than one half of one percent (0.46%). Also, such death rates in the recent past are likely to come down over time, because they happened before promising new clinical trials of antiviral drugs that proved effective against more deadly viruses such as SARS, HIV and Ebola.

For perspective, the SARS coronavirus killed 774 people out of 8096 known cases in 2003, which was a death rate of 9.6% before it vanished the next year. Bird flu in 1997 was predicted to be a deadly pandemic, but it killed very few people before it disappeared. In its February 22 U.S. Influenza Surveillance Report, “CDC estimates that so far this season there have been at least 32 million flu illnesses… and 18,000 deaths from flu.” Dividing 18,000 by 32 million implies a low U.S. death rate of .0138% from the flu.

Looking at the death rate alone is obviously not enough: We also have to look at the numbers of people infected, and the duration of the epidemic, which is why the flu killed so many more people than SARS. Still, it is important to avoid scaring people about the risk of death from COVID-19 by continuing to ignore the fact that the vast majority of cases “have mild disease and get better without needing any special care.”

This originally appeared in the Cato @ Liberty blog.

Gavi | Vaccination

Immunization Effort to Avert over 605,000 Cervical Cancer Deaths

“By 2023, Gavi had worked with over 40 countries to provide the HPV vaccine to 23.7 million girls. This massive immunisation effort is projected to avert over 605,000 future deaths from cervical cancer, a testament to the vaccine’s life-saving potential.

In 2023 alone, Gavi-supported countries vaccinated more than 14 million girls – more than the total number vaccinated in the previous decade combined. Thanks to an unprecedented scale-up of vaccine introductions, dedicated investment and expanded access since 2023, Gavi is on track to reach its ambitious goal of protecting 86 million girls with the HPV vaccine by 2025, a milestone that is expected to prevent more than 1.4 million future cervical cancer deaths.”

From Gavi.

Our World in Data | Vaccination

Measles Vaccines Save Millions of Lives Each Year

“Measles used to be an extremely common disease. Just sixty years ago, over 90% of children would have been infected by it, and of those who developed symptoms, around a quarter would be hospitalized.

The United States alone had around three to four million cases annually, leading to tens of thousands of hospitalizations and hundreds of deaths each year.

However, in 1963, John Enders developed the first effective measles vaccine. Vaccination efforts ramped up rapidly in richer countries, and in the 1970s and 1980s, they were scaled up worldwide.

In just the last fifty years, it’s estimated that measles vaccinations have prevented over ninety million deaths worldwide. Two to three million people would die from measles every year without them.”

From Our World in Data.

Clinical Trials Arena | Vaccination

Stablepharma Begins Trial of “World-First” Fridge-Free Vaccine

“The first patient has been dosed in a Phase I trial of Stablepharma’s tetanus-diphtheria vaccine, which does not need to be refrigerated.

The vaccine candidate, SPVX02, is completely stable at room temperature, and in testing was fully potent after three cycles of extreme temperature fluctuations ranging from -20°C to 40°C.  The candidate has been developed to withstand these temperatures through the company’s StablevaX technology.

In what is being branded a ‘world-first’, the first patient in the trial of SPVX02 was dosed earlier this month at a National Health Service (NHS) site in the UK. The vaccine doses of SPVX02 being used in the Phase I study also have an 18-month shelf life.”

From Clinical Trials Arena.

Ars Technica | Vaccination

New RSV Treatment Linked to Fall in Baby Hospitalizations

“Far fewer babies went to the hospital struggling to breathe from RSV, a severe respiratory infection, after the debut of a new vaccine and treatment this season, according to an analysis published today by the Centers for Disease Control and Prevention…

For the new study, CDC researchers looked at RSV hospitalization rates across two different RSV surveillance networks of hospitals and medical centers (called RSV-NET and NVSN). They compared the networks’ hospitalization rates in the 2024–2025 RSV season to their respective rates in pre-pandemic seasons between 2018 and 2020. The analysis found that among newborns (0–2 months), RSV hospitalizations fell 52 percent in RSV-NET and 45 percent in NVSN compared with the rates from the 2018–2020 period.”

From Ars Technica.